Darovasertib+Crizotinib Slashes Progression Risk by 58%, Paving Way for H2 2026 NDA
Summary
IDEAYA Biosciences announced highly positive topline results from its Phase 2/3 registrational trial for darovasertib in combination with crizotinib. The combination significantly reduced the risk of progression by 58% and demonstrated a median Progression-Free Survival (PFS) of 6.9 months compared to 3.1 months for investigator choice therapy, with an objective response rate (ORR) of 37.1% versus 5.8%. This news follows the company's 8-K filing earlier today, which broadly announced positive topline results, and a Dow Jones Newswires report on April 10th indicating results would be released today. These robust clinical trial results are a major positive catalyst, significantly de-risking the drug candidate and supporting the company's plan for a U.S. New Drug Application (NDA) submission in the second half of 2026. This data could drive substantial investor confidence and stock appreciation. Investors will now focus on the upcoming NDA submission and the presentation of additional OptimUM-02 data at a major medical conference, which could provide further details and reinforce the drug's profile.
At the time of this announcement, IDYA was trading at $42.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $13.45 to $39.28. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.